Efficacy study on 43,548 participants: https://www.nejm.org/doi/full/10.1056/nejmoa2034577
CONCLUSIONS -A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older.
That is Relative Risk Reduction (RRR) and NOT Absolute Risk Reduction (ARR) which is less than 1% (0.84%). There is a great deal of risk to assume for a less than 1% risk reduction in catching covid. Especially considering the minute percentage of covid + people who actually get hospitalized.
In the study group of 18K+, 8 people got covid and in the control group 162 got covid. Plus it was unblinded EARLY with only 2 months of observation. SO there is NO WAY to get long-term safety and risk data.
Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials - PubMed
Relative risk reduction and absolute risk reduction measures in the evaluation of clinical trial data are poorly understood by health professionals and the public. The absence of reported absolute risk reduction in COVID-19 vaccine clinical trials can lead to outcome reporting bias that affects...
Further, considering the FDA seems to be bent on not allowing the taxpayers (WHO FUNDED THE RESEARCH via DARPA, ) to see the study. Who is the government working for? Hint, it's not the people.
